Gravie nabs $10.5 mln Series A funds

Gravie said Monday that it has secured $10.5 million in Series A financing. Aberdare Ventures led the round with participation from previous backer FirstMark Capital. In conjunction with the funding, Dr. Mohit Kaushal of Aberdare Ventures has been added to Gravie’s board of directors. Based in Minneapolis, Gravie is an insurance marketplace.

Cervel Neurotech Announces Financing

Cervel Neurotech, a privately held company developing a novel, non-invasive and non-pharmacologic therapy for depression, pain and other conditions, has completed a funding round of $14.1 million. The company’s existing investors, D. E. Shaw Ventures and Aberdare Ventures, participated in the equity financing.

Kaushal Joins Aberdare Ventures

Aberdare Ventures said Tuesday that Mohit Kaushal has joined the firm as a partner. He will focus on Aberdare’s investments in technologies and services that will drive healthcare efficiency. Kaushal was most recently West Health’s chief strategy officer and EVP of business development.

sunrise

peHUB First Read

This morning find out about the Boston tech community raising money for the marathon bombing victims, why pension funds are hooked on PE and if you’re interested we have the link for the top ten private equity loopholes.

RxAnte Secures Funding led by Aberdare Ventures

RxAnte, a healthcare improvement company has raised Series A financing led by Aberdare Ventures with additional backing from the West Health Investment Fund. The financing will be used to further develop RxAnte’s proprietary technologies, commercialize its current offerings, and expand the company’s impact on the quality of medication use.

Lpath Appoints to Aberdare Ventures Partner to Board

Lpath has appointed Daniel L. Kisner to its board of directors. Most recently, Kisner served as a partner at Aberdare Ventures and, prior to that, he was president and CEO of Caliper Technologies, leading its development from a start-up focused on microfluidic lab-on-a-chip technology to a publicly-traded organization. PRESS RELEASE Lpath, Inc. (OTCQB: LPTN), the […]

MC10 Gets Backing from Aberdare Ventures

Healthcare technology company MC10 has closed on a $2 million investment from Aberdare Ventures and added managing partner, Paul Klingenstein, to its board of directors. MC10 is headquartered in Cambridge, MA. PRESS RELEASE MC10 Inc. today announced it has closed on a $2 million investment from Aberdare Ventures and added managing partner, Paul Klingenstein, to […]

Aviir Seals Agreement for Up to $30M in Funding

Irvine, Calif.-based biotech company Aviir Inc. announced Tuesday that it had sealed an agreement with investors to raise up to $30 million. The financing includes an initial investment of $10 million and future investments of up to $20 million upon achieving certain milestones. Merck Global Health Innovation Fund led the round. Current investors Bay City Capital, Aberdare Ventures, and New Leaf Venture Partners also participated.

Nevro Inks $58M For Chronic Pain Treatment

Menlo Park, Calif.-based Nevro Corp., a neuromodulation company focused on relief of chronic pain, has sealed a whopping $58 million round led by new investor Johnson & Johnson Development Corporation. Existing shareholders Aberdare Ventures, Accuitive Medical Ventures, Bay City Capital, Mayo Clinic, MPM Capital and Three Arch Partners also participated. The money will go toward a clinical study in the US and to support the company’s commercialization strategy.

NxThera Adds $12.6M Series B

NxThera Inc., a St. Paul, Minn.-based medical devices company, has added $12.6 million in Series B financing. American Medical Systems Inc. led the round, and was joined by existing investors Arboretum Ventures, Aberdare Ventures and GDN Holdings. NxThera is developing medical technologies to treat a variety of endourology conditions.

VertiFlex Gets VC Backing

New Enterprise Associates, Aberdare Ventures, Alta Partners and Thomas, McNerney & Partners backed VertiFlex, the spinal support products developer, with $14 million and have an option to provide the company with another $14 million within the next 12 months.

HemaQuest Pharma Raises $12 Million

HemaQuest Pharmaceuticals, a Newton, Mass.-based developer of small-molecule therapeutics to treat serious blood disorders, has raised $12 million in Series B funding. Aberdare Ventures led the round, and was joined by return backers De Novo Ventures, Forward Ventures and Lilly Ventures. HemaQuest previously raised $20 million.

Clovis Oncology Raises $145 Million

Clovis Oncology, a developer of anti-cancer agents based in Boulder, Colo., secured $145 million in financing from Domain Associates, New Enterprise Associates (NEA), Versant Ventures, Aberdare Ventures, Abingworth, Frazier Healthcare Ventures, ProQuest Investments and the Company’s management team. Press release: Clovis Oncology, Inc., a company focused on acquiring, developing and commercializing innovative anti-cancer agents in […]

PEHUB Community

Join the 12500 members of peHUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

Psst! Got any hot tips?

  • This field is for validation purposes and should be left unchanged.

PE HUB News Briefs

RSS Feed Widget

Marketplace

VCJ Headlines (subscribers only)

RSS Feed Widget

Buyouts Headlines (subscribers only)

RSS Feed Widget

Reuters VC and PE feed

RSS Feed Widget